Skip to main content
MEMPHASYS LIMITED. logo

MEMPHASYS LIMITED. — Investor Relations & Filings

Ticker · MEM ISIN · AU000000MEM5 LEI · 549300RZ3LBXHF3WXL97 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2009-03-12 Regulatory Filings
Country AU Australia
Listing ASX MEM

About MEMPHASYS LIMITED.

https://www.memphasys.com/

Memphasys Limited is a biotechnology company specializing in the development of advanced cell separation and reproductive biotechnology solutions. The company's core technology platform utilizes proprietary membranes and electrophoresis to isolate high-quality cells from biological fluids. Its flagship product, the Felix™ system, is an automated device designed for the rapid separation of high-quality sperm from semen samples for use in human assisted reproductive technology (ART) procedures. This technology aims to improve clinical outcomes by selecting sperm with lower DNA fragmentation and higher motility compared to traditional centrifuge-based techniques. Beyond human fertility, the company applies its bio-separation expertise to animal health, including diagnostic tools for stallion fertility. Memphasys focuses on providing innovative solutions that enhance efficiency and success rates in the global reproductive health market.

Recent filings

Filing Released Lang Actions
NuSep EGM Presentation 48 pages ?Kb
Regulatory Filings
2009-03-12 English
Suspension from Official Quotation 1 page ?Kb
Delisting Announcement Classification · 95% confidence The document is a market release announcing the suspension of NuSep Limited's securities from official quotation due to compliance issues related to a change in the company's activities after an acquisition. It is an official notice about the stock being removed from trading, which fits the definition of a Delisting Announcement. The document is short and focused solely on the suspension notice, not a full report or financial data.
2009-03-12 English
ASX Circular - Reorganisation of Capital 1 page ?Kb
Share Issue/Capital Change Classification · 95% confidence The document announces a reorganisation of the company's capital structure, specifically a share consolidation (every 20 shares consolidated into 1 share). It includes a timetable for shareholder approval, trading dates, and changes in ASX codes. The document is short (1104 characters) and serves as an announcement rather than a detailed report or financial statement. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues, stock splits, or other capital changes.
2009-03-12 English
Prospectus To Acquire NxGen 82 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus lodged with ASIC by NuSep Limited regarding a capital raising offer to acquire NxGen Pharmaceuticals. It includes extensive information about the offer, the timetable for the transaction, details about the company and NxGen, and the terms of the share issue and options. The document is clearly a formal offer document for new shares and options, describing the capital raising and acquisition transaction. It is not an annual report, earnings release, or management discussion. It is not a regulatory announcement or a simple notice but a full prospectus for a capital raising and acquisition. Therefore, the document fits the category of Capital/Financing Update (CAP). The confidence in this classification is high given the explicit references to the prospectus, share offer, and acquisition details.
2009-03-10 English
NuSep Half Year Report and Accounts 19 pages ?Kb
Regulatory Filings
2009-02-26 English
NSP The NxGen Business 4 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document provides detailed information about the NxGen business that NuSep is acquiring, including product descriptions, market positioning, financial summaries for fiscal years ending June 2008 and June 2009, and comparative market data. It includes financial figures such as revenue, gross profit, EBITDA, and profit, as well as strategic and operational details about NxGen's products and market plans. The document references an Investigating Accountant's Report and an Independent Expert's Report contained in a Notice of Meeting dated 13 February 2009, indicating this is part of acquisition-related disclosures. The content is comprehensive and includes substantive financial data and business analysis, not merely an announcement or summary. It is not a regulatory filing, certification, or a short announcement. The document is consistent with a Capital/Financing Update (CAP) as it provides detailed information on a business acquisition and related financials, which is typical for financing or capital structure updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2009-02-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.